Asensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery Program
Asensus Surgical, Inc. announced that Sendai Tokushukai Hospital in Japan has initiated a Senhance Surgery Program, leasing a Senhance Surgical System, becoming the second institution within one of Japan's largest private hospital systems to do so. The system offers innovative features like haptic feedback, enhancing surgical capabilities. This collaboration aims to elevate patient care and outcomes, aligning with the hospital's commitment to excellence.
Sendai Tokushukai Hospital in Japan has initiated a Senhance Surgery Program, leasing a Senhance Surgical System.
The system offers innovative features like haptic feedback, enhancing surgical capabilities.
The collaboration aims to elevate patient care and outcomes, aligning with the hospital's commitment to excellence.
- None.
Insights
The lease of a Senhance Surgical System by Sendai Tokushukai Hospital in Japan represents a strategic business development for Asensus Surgical. The adoption of such advanced technology by one of the largest private hospital networks in Japan could signal market confidence in Asensus Surgical's offerings and might indicate a potential growth avenue in the highly competitive medical device industry. The Senhance System's unique haptic feedback technology, which provides tactile sensations to the surgeon, might be a significant differentiator in the market. This feature can help in minimizing surgical errors and improving patient outcomes by providing a more intuitive surgical experience.
For investors, this partnership could be seen as an indicator of the system's acceptance and possible widespread adoption, potentially driving long-term revenue growth for Asensus Surgical. This expansion into markets like Japan, known for their high standards in healthcare technology, may also enhance the company's reputation globally. However, the financial impact will greatly depend on how well the technology is received by the healthcare community and whether it translates into further purchases or leases.
The leasing of a robotic surgical system to a major hospital provides relevant insights into the penetration of robotic surgery in the healthcare market. Japan, as a technologically advanced nation, is often a bellwether for the adoption of cutting-edge medical technologies. As such, the market's response to the Senhance System could provide a barometer for its potential acceptance in other developed countries.
The value proposition of a robotic surgical system often hinges on the potential to reduce complications and improve surgical outcomes, which can ultimately lead to cost savings for healthcare providers, despite the upfront investment. Thus, the performance and economic benefits of the Senhance System in a real-world clinical setting could influence the stock market investor by providing a case study for the return on investment these systems may offer.
It is important to monitor the outcomes of surgeries and the overall satisfaction of both patients and healthcare providers with the Senhance System. Positive results could lead to increased sales or leases, while any drawbacks could hinder market adoption. Investors should be aware of these potential developments and their implications for Asensus Surgical's stock performance.
Second System to be Utilized by one of the Largest Private Hospital Systems in Japan
RESEARCH TRIANGLE PARK, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced that Sendai Tokushukai Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System.
"We're happy that Sendai Tokushukai Hospital has initiated a lease on the Senhance System, becoming the second institution within one of Japan's largest private hospital systems to do so," said Anthony Fernando, President and CEO of Asensus Surgical. "This underscores the growing trust in Asensus Surgical's technology in Japan, and we're excited to collaborate with Sendai Tokushukai Hospital to enhance surgical standards."
“On behalf of Sendai Tokushukai Hospital we are pleased to lease a Senhance System in our facility,” said Kei Kawaguchi, Chief of Surgery. “The Senhance System offers innovative features such as haptic feedback, enhancing our surgical capabilities and facilitating precise procedures. Through this collaboration, we aim to elevate patient care and outcomes, aligning with our commitment to excellence.
The Senhance Surgical System is the only commercially available robotic surgery system with haptic feedback, a differentiating feature for surgeons.
About Sendai Tokushukai Hospital
Established on February 1, 1985, Sendai Tokushukai Hospital is a respected general and acute care facility. Under the leadership of Shinichi Higashiue and administratively managed by Hisayoshi Inoue, the hospital serves as an essential healthcare provider in the region and offers a diverse range of medical services, including Internal Medicine, Gastroenterology, Surgery, Orthopedics, and others. The Tokushukai Medical Group Facility oversees 71 hospitals across Japan and their philosophy is “All living beings are created equal”. Under this philosophy, they continuously strive for realizing “Anybody in the society is to receive the best possible medical care anywhere, whenever necessary”. From Emergency Medical Care to preventive health care, chronic care and advanced care, we provide the optimal medical care.
About Asensus Surgical, Inc.
Asensus Surgical is revolutionizing surgery with the first intra-operative Augmented Intelligence technology approved for use in operating rooms around the world. Recognized as an award-winning leader in digital technology, Asensus is committed to making surgery more accessible and predictable while delivering consistently superior outcomes. The Company’s novel approach to digitizing laparoscopy has led to system placements globally. Led by engineers, medical professionals, and industry luminaries, Asensus is powered by human ingenuity and driven by collaboration. To learn more about the Senhance® Surgical System and the new LUNA™ System in development, visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc/
X: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
TikTok:https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance Surgical System and Sendai Tokushukai Hospital in Japan initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute "forward looking statements'' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether Asensus Surgical can accelerate the adoption of the Senhance Surgical System throughout Japan and other key geographies around the world and whether the Senhance Surgical System will enable Sendai Tokushukai Hospital to elevate its patient care and outcomes. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 21, 2024 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie
ICR Westwicke
invest@asensus.com
443-213-0499
MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ba0a44c-320c-4698-b7f1-5149c823ad60
FAQ
Which hospital in Japan has initiated the Senhance Surgery Program?
What innovative features does the Senhance Surgical System offer?
What is the goal of the collaboration between Asensus Surgical and Sendai Tokushukai Hospital?
